Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (126)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (284)
  2. Breast Medicine Service (284)
  3. Department of Medicine (284)
  4. GSK Faculty (284)
  5. Human Oncology and Pathogenesis Program (284)
  6. Solid Tumor Oncology Division (284)

More Groups

People
  1. Pedram Razavi (78)
  2. Jorge Reis-Filho (64)
  3. Neal Rosen (57)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (42)

More People

Years
  1. 2025 (14)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (37)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (284)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PI3K mutations are more common in low grade DCIS
    Meeting Abstract

    Sakr, R.; Chandarlapaty, S.; Andrade, V.; Giri, D.; Muhsen, S.; Paik, W.; Morrow, M.; Rosen, N.; King, T.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Alternate mechanisms of PI3K pathway activation among subtypes of ductal carcinoma in situ suggest distinct pathways for progression to invasive disease
    Meeting Abstract

    Sakr, R.; Chandarlapaty, S.; Barbashina, V.; Andrade, V.; Heguy, A.; Morrogh, M.; Olvera, N.; Paik, W.; Arroyo, C.; Morrow, M.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
    Meeting Abstract

    Rodrik - Outmezguine, V. S.; Cao, N.; Chandarlapaty, S.; She, Q. B.; Ye, Q.; Smith, P.; Guichard, S.; Rosen, N.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Journal Article

    Scaltriti, M.; Chandarlapaty, S.; Prudkin, L.; Aura, C.; Jimenez, J.; Angelini, P. D.; Sánchez, G.; Guzman, M.; Parra, J. L.; Ellis, C.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma
    Journal Article

    Sakr, R.; Barbashina, V.; Morrogh, M.; Chandarlapaty, S.; Andrade, V. P.; Arroyo, C. D.; Olvera, N.; King, T. A.
    Applied Immunohistochemistry & Molecular Morphology (2010)

    Fulltext@MSK | Save
  • Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
    Journal Article

    Chandarlapaty, S.; Scaltriti, M.; Angelini, P.; Ye, Q.; Guzman, M.; Hudis, C. A.; Norton, L.; Solit, D. B.; Arribas, J.; Baselga, J.; more...
    Oncogene (2010)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively dependent on Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K.; Leander, K.; DeFeo-Jones, D.; Huber, H.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling
    Journal Article

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    PLoS ONE (2008)

    Fulltext@MSK | Save